Adenocarcinoma of the lung constituted 9% of all lung carcinomas in men 30 years ago.
A b s t r a c t
Adenocarcinoma of the lung constituted 9% of all lung carcinomas in men 30 years ago. 1 During the last several decades, its incidence has been increasing. [2] [3] [4] [5] [6] [7] [8] It is the most common cell type in females and in nonsmoking patients, and it is the most common tumor subtype in some regions of the world. [9] [10] [11] [12] [13] [14] The incidence of bronchioloalveolar carcinoma (BAC) is also increasing. [15] [16] [17] Many studies have evaluated pathologic prognostic features of adenocarcinomas, including cell types, architectural patterns, and stage. The majority these studies have not specifically examined Tl NO MO adenocarcinomas. Some studies used the previous definition of a stage I carcinoma and included patients with Nl metastases, other studies grouped adenocarcinomas with non-small cell carcinomas, and many have grouped Tl with T2 carcinomas. 18~38 This has left a dearth of attention directed toward identifying prognostic factors for patients with Tl NO MO adenocarcinomas and BACs that undergo curative surgical excision. Prognostic features for this group of patients are important because the 5-year disease-free survival of patients with Tl NO MO adenocarcinoma is 66% to 85%. 39^6 Separation of adenocarcinomas from other pulmonary carcinomas and examining the subset of patients with Tl disease is essential to understand the metastatic potential and prognostic strength of pathologic factors of the different tumors included under the rubric of stage I adenocarcinoma and BAC. 43 In addition, the prognostic significance of distinguishing between BAC and conventional adenocarcinoma and the threshold for amount of central fibrosis allowable within the BAC category for prognostication has not been defined fully. Finally, the identification of prognostic variables within this group of patients is important for future adjuvant therapy studies to identify the subset of patients that are at higher risk of having an adverse carcinoma-related outcome.
We retrospectively studied 218 cases of completely resected, surgically staged, Tl NO adenocarcinomas and BACs to identify significant pathologic prognostic factors related to disease-free survival.
Materials and Methods
An initial computer search was performed of the surgical pathology files of the William Beaumont Hospital, Royal Oak, MI, for adenocarcinomas and BACs during the period August 1, 1975, through December 30, 1995. Cases were excluded from the list if the gross tumor measurement was greater than 3.0 cm, carcinoma extended onto the pleural surface, lymph node metastases were present, or adenocarcinoma was present at the bronchovascular surgical margin. Cases also were excluded if the patients had not undergone a lobectomy procedure or the lymph nodes from the mediastinal drainage regions were not sampled. The clinical files of the remaining cases were reviewed by one of us (S.P.) or by the William Beaumont Tumor Registry to obtain follow-up information and exclude the cases with metastases or other pulmonary tumors at the time of surgery or for which follow-up information was not available. All slides from all cases were requested from the William Beaumont Hospital pathology storage facilities. If the original slides were not available for review, the blocks were recut. Additional cases were excluded from the study if, on review, the tumor was of adenosquamous, large cell undifferentiated, or large cell neuroendocrine type or had neuroendocrine cytologic features. 47 The presence of mucicarmine-stained material within a morphologically large cell undifferentiated carcinoma was considered to be a poorly differentiated adenocarcinoma.
The study included 218 cases. All patients had completely excised, surgically staged, Tl NO adenocarcinoma or BAC treated by lobectomy and mediastinal lymph node staging.
Pathologic Features
All slides from all cases were reviewed by 2 of us (N.S.G. and A.M.) without knowledge of the outcome for the patient. The following features were examined and recorded: Hmage6l Edge of an adenocarcinoma. An imaginary line drawn between the 2 arrows separates malignant cells that clearly line alveolar septa (right of imaginary line) from haphazardly arranged glandular structures that could be invasive glands or markedly distorted alveoli (left of imaginary line). The latter region was considered the minimum amount of distortion required to be considered a region of central fibrosis (H&E, x28.8).
less than 5% central fibrosis. 21, [51] [52] [53] Classic sclerosing
BACs had 6% to 25% central fibrosis. 9. Tumor necrosis, classified as less than 50% or more than 50% of tumor volume.
The actuarial probability of remaining free of nonpulmonary metastases (disease-free survival) was calculated by using the Kaplan-Meier method, and the statistical significance of the differences between the metastases-free probabilities of the various factors was determined by the log-rank test. Statistical analyses of the differences for categoric outcomes were determined by using the Fisher exact test or the % 2 .
Stepwise logistical regression modeling for the development of nonpulmonary metastases was used for testing the association of each prognostic factor with the development of nonpulmonary metastases after controlling for the effects of the remaining factors. The Statistical Analysis System statistical program (SAS Inc, Cary, NC) was used for the analyses.
Results
The mean age at diagnosis was 65 years (range, 32-88 years; SD, 11 years). The mean overall follow-up period was
•Image 71A fibrous septum divides an adenocarcinoma. It is unclear whether the arrangement of the neoplastic acinar structures to the right of the septum are malignant glands or alveolar spaces lined by malignant cells. Therefore, this architectural pattern was considered fibrotic. The alveolar structural pattern is retained to the left of the septum; fibrosis was considered to be absent in this region (H&E, x76.8).
5.9 years (range, 6 days to 21.2 years; SD, 4.7 years). The median number of carcinoma slides examined was 3.4 (range, 1-12; SD, 1.8).
Of the 218 patients, 148 (67.8%) were disease-free during their follow-up period; no nonpulmonary metastases or another lung tumor developed during the follow-up period. In 57 patients (26.1%), nonpulmonary metastases developed. The most common site of initial metastases was the brain (19 [33%] ). The second most common site was the mediastinum (13 [23%] ). Of the patients in whom mediastinal lymph node metastasis developed, the shortest period from surgery until the metastasis was identified was 4.8 months. The brain was the initial location in the patient in whom metastasis developed 1 month after surgery. The median follow-up periods for the patients who were diseasefree and those in whom nonpulmonary metastases developed was 6.3 years and 2.1 years, respectively liable II.
A new lung carcinoma developed in 10 (4.6%) of 218 patients. The significance of the second neoplasm and whether it was a second primary neoplasm or a metastasis from the initial lung carcinoma was unclear. 54 Therefore, these cases were separated from those in which nonpulmonary metastases developed. In 3 (1.4%) of 218 patients, new lung carcinoma and nonpulmonary metastases developed during the follow-up period. For the same reasons as the (5) 10 (18) 44 (77) 1 (2) 1 (2) 4(7) 8 (14) 14 (24) 29 (51) 5 (9) aforementioned group of cases, these cases were separated from those in which nonpulmonary metastases developed.
The following analyses compared disease-free cases with those in which nonpulmonary metastasis developed.
Univariate Analysis
The median maximum dimension of the adenocarcinomas for all cases was 1.8 cm (range, 0.5-3.0 cm; SD, 0.7 cm) liable 21. The median maximum dimension of the adenocarcinomas in the disease-free group was 1.6 cm (range, 0.5-3.0 cm; SD, 0.7 cm) compared with a median dimension of 2.3 cm (range, 0.5-3.0 cm; SD, 0.7 cm) in the nonpulmonary metastases group. Of the 148 cases in the disease-free group, 25 (16.9%) had adenocarcinomas 1.0 cm or smaller, and 60 (40.5%) had adenocarcinomas larger than 2.0 cm. In contrast, the nonpulmonary metastases group had a significantly different adenocarcinoma maximum dimension distribution (P < .01); 3 (5%) patients had adenocarcinomas 1.0 cm or smaller, and 44 (77%) had adenocarcinomas larger than 2.0 cm. The differences in maximum tumor dimension between the 2 groups also was statistically significant when maximum dimension was treated as a continuous variable (P < .01).
The differences in the most common and highest nuclear grades between the 2 groups were statistically significant (P < .01). In the disease-free group, the most common nuclear grade in the adenocarcinomas was 1 in 64 cases (43.2%) compared with 5 (8%) of the nonpulmonary metastases cases. Only 58 (39.2%) of the disease-free cases had adenocarcinomas in which the highest nuclear grade was 3 compared with 39 (68%) of the nonpulmonary metastases cases. Total nuclear grade (most common + highest) also was significantly different between the groups when analyzed using the yj and linear regression tests (P < .01).
The presence of lymphatic vascular space invasion was significantly different between the 2 groups (P < .01). Tumor necrosis greater than 50% also was significantly different between the 2 groups (P < .01).
Features that were not significantly different between the 2 groups included mucinous vs nonmucinous adenocarcinoma cell type (P = .28) and adenocarcinoma architecture (P = .11).
Examination of the histologic features from cases in which nonpulmonary metastases developed revealed that 77% of the patients had adenocarcinomas larger than 2.0 cm. Of the 57 patients, 52% had adenocarcinomas that were greater than 2.0 cm in maximum diameter, had more than 50% central fibrosis or solid tumor, and had a highest nuclear grade of 3. In contrast, only 3.5% of the nonpulmonary metastases developed in patients with adenocarcinomas that were less than 2.0 cm in maximum dimension, had less than 25% central fibrosis, and had a highest nuclear grade of 1.
Survival Analysis (Kaplan-Meier Actuarial Curves)
The overall 1 -, 2-, 3-, 4-and 5-year disease-free survival values were 93%, 85%, 79%, 74%, and 72%, respectively. The nonpulmonary metastases-free survival advantage for patients without vascular space invasion was significant (P < .01); 78% of patients were disease free at 5 years when vascular space invasion was absent compared with only 35% when vascular space was present ITable 31 and IFigure II. Most nonpulmonary metastases developed within the first 3 years after surgery. Maximum tumor dimension stratified by centimeters had significant 5-year disease-free survival differences (P < .01); 87% of patients with adenocarcinomas 1.0 cm or smaller were disease-free at 5 years compared with 83% of those with adenocarcinomas larger than 1.0 cm but 2.0 cm or smaller and 60% of patients with adenocarcinomas larger than 2.0 cm IFigure 21. Patients with adenocarcinomas with increasing amounts of central fibrosis, more than 50% necrosis, and increasing most common and highest nuclear grades also had significantly poorer 5-year nonpulmonary metastases-free survival values. Adenocarcinoma architecture and mucinous cell type showed no significant 5-year disease-free survival differences (P = .19 and P = .59, respectively).
Multivariate Analysis
Stepwise logistical regression, entering all of the features significant in univariate analysis and modeling for the development of nonpulmonary metastases, identified maximum tumor dimension, the presence of lymphatic vascular space invasion, and increasing central fibrosis as significantly related to the development of nonpulmonary metastases ITable 41. Maximum tumor dimension and increasing tumor fibrosis were treated as continuous variables in this model. A second analysis, treating the maximum tumor dimension (< 1.0 cm, 1.1 -2.0 cm, and 2.1 -3.0 cm) and amount of tumor fibrosis (greater or less than 50% fibrosis) as categoric variables found that increasing tumor size, a greater highest nuclear grade, and vascular space invasion were significantly associated with the development of nonpulmonary metastases ( Table 4) . The entire analysis (univariate, survival, and multivariate) was performed excluding the 13 cases in which mediastinal metastasis initially developed. The analysis was performed to evaluate potential differences between mediastinal (local) and distant metastases and to ensure that the cases in which mediastinal metastases developed did not represent surgical understaging. There were no significant differences between the 2 analyses. The median follow-up period in the distant metastases-only group was slightly longer but was not significantly different than that of the overall group. Lymphatic vascular space invasion, maximum tumor dimension, and highest nuclear grade were significant in the stepwise logistical and actuarial survival curve analyses. Unlike the first analysis, the amount of central fibrosis and the most common and total nuclear grade were not significant in either of these analyses. The amount of necrosis was not significant in any of the analyses.
Discussion
We studied 218 cases of Tl NO M0 conventional adenocarcinomas and BACs. The overall 5-year disease-free survival was 72%. This value is similar to the results found by other authors, who have reported a 66% to 85% 5-year disease-free survival. 3^46 Features that had a significant and consistent association with nonpulmonary metastases were increased maximum tumor dimension, lymphatic vascular space invasion, increased amounts of central fibrosis, and greater highest nuclear grade. These features also were significant when we excluded the cases in which mediastinal metastasis initially developed. This suggests that the latter cases were not surgically understaged, and mediastinal metastases have similar relationships as distant metastases in regard to the characteristics of the primary adenocarcinoma or BAC that portend metastases. 55 Maximum dimension of the adenocarcinoma was significantly related to nonpulmonary metastases and metastasesfree survival in univariate and multivariate analysis. This finding is not surprising; many authors have found that patients with larger neoplasms have a poorer survival than patients with smaller neoplasms, including patients with neoplasms smaller than 3.0 cm. 52 77 We believe that these disparate results can be attributed to differences in the patient populations studied. Most of the studies included patients with different types of neoplasms of different stages, using the presence or absence of vascular space invasion as the criterion against which outcome was measured. It is unanimously clear that large vessel vascular space invasion is common in pulmonary adenocarcinomas, ranging from 34% to 100%, with most studies identifying it in 60% to 85% of neoplasms. 84 One study identified arteriolar invasion in 81% of adenocarcinomas less than 3.0 cm in maximum dimension. 82 Because of the frequent occurrence of large vessel vascular space invasion and the relatively lower incidence of metastases in these patients, we believe that its prognostic significance is dubious. Therefore, we chose to study only lymphatic vascular space invasion. In support of our choice are 3 studies 28 -37 ' 77 that examined the prognostic significance of large vessel and lymphatic vascular space invasion. All 3 found that only lymphatic vascular space invasion was significantly related to decreased survival.
We found lymphatic vascular space invasion to be a significant prognostic parameter for nonpulmonary metastases in univariate, stepwise logistical regression, and actuarial curve analysis. Our data suggest that the presence of lymphatic vascular space invasion in a resection specimen indicates that malignant cells have metastasized in most patients, despite the absence of identifiable lymph node metastases. Patients with lymphatic vascular invasion had a 5-year nonpulmonary metastases-free survival of 35%, which is similar to the prognosis of patients with stage Ilia carcinoma. 43 These results are similar to those of Shields, 77 who found that patients who had stage I disease and lymphatic vascular space invasion had the same survival as patients with stage Nl nodal metastases. Macchiarini et al 85 also demonstrated that small vascular space invasion was a predictor of decreased survival in patients with stage I disease. The lack of finding peribronchial and mediastinal lymph node metastases in these patients may reflect the presence of micrometastases in these lymph nodes that are not recognizable on routine H&E stains. 86 It is imperative that pathologists identify lymphatic vascular space invasion. Compared with the other prognostic features, identification of lymphatic vascular space invasion is the most pathologist-dependent. We agree with the statements made by Collier et al 80 in 1958: "blood vessel invasion has seemed so important in the determination of the prognosis, the burden of proof that no vascular invasion is present is on the pathologist," and "the most frequently missed excluding factor (by pathologists) is vascular invasion." Identification of lymphatic vascular invasion is dependent on thorough sampling of the tumor. It is important that several tumor blocks are examined to avoid underestimation of blood vessel invasion. 28 The identification of vascular space invasion has been shown to increase when greater numbers of tumor blocks are submitted. 87 Tumor grade has the same issues as vascular space invasion in regard to the literature and inclusion of patients with different stages and tumor types. Most analysis data of an almost 2-fold larger odds ratio for lymphatic vascular space invasion compared with highest nuclear grade when tumor size and central fibrosis were treated as categoric variables.
As mentioned in the "Materials and Methods" section, we quantified the amount of central fibrosis or scar to circumvent the classification of tumors as adenocarcinoma or BAC and to evaluate the relationship between the amount of central fibrosis and prognosis. This feature also addresses the prognostic significance of solitary typical BAC, sclerosing BAC, adenocarcinoma with an extensive BAC pattern, conventional adenocarcinoma, and scar-associated adenocarcinomas. Each of these neoplasms has its own controversial facets and its own body of literature. The neoplasms have been viewed previously as distinct neoplasms, based primarily on morphologic differences. Our data and recent studies suggest that they represent a continuum, with parenchymal invasion, stromal desmoplasia (central fibrosis), and lymphatic vascular space invasion functioning as key pathologic phenomena leading to metastases. 90 Shimosato et al 91 graded the amount and quality of the central fibrotic region within adenocarcinomas as a "fibroblastic focus score" using the following increasing focus score classification: none or minimal, fibroblastic tissue with a small amount of collagen, fibroblastic tissue with a moderate or abundant amount of collagen, and hyalinized tissue. When examining patients with Tl (all N and M categories) adenocarcinomas, they found a correlation between higher fibroblastic focus scores, vascular invasion, and outcome. These correlations were significant for adenocarcinomas less than 2 cm in maximum dimension, but the smaller the adenocarcinoma, the smaller and lower the fibroblastic score. The characteristic of the fibroblastic focus was a good morphologic predictor of patient outcome. These findings were confirmed by other authors. We evaluated only the quantity of central fibrosis based on the quartile of the adenocarcinoma diameter that was fibrotic or collagenized instead of evaluating the quality and quantity of the central fibrosis as done by Shimosato et al. 91 We chose this system because it is simple, thus lending itself to easy incorporation into surgical specimen reports by pathologists. Despite the lack of a qualitative component in our central fibrosis grading system, our results are almost identical to those of Shimosato et al. 30, 91 The tumors we classified as having more than 75% central fibrosis were identical to those in the photographs of tumors classified as fibrosis with hyalinization by Shimosato et al. 30, 91 The validity of our central fibrosis quantification system is supported by the findings of Yamashiro et al, 34 who found a significant relationship between survival and amount of fibrosis using a classification system of none, less than 30%, or more than 30%. 51 However, in a followup study 2 years later, he found that patients with sclerosing BACs had a survival rate similar to patients with typical adenocarcinoma with sclerosis. 52 In his opinion, sclerosing
BACs constituted a significant proportion of the so-called scar carcinomas. We chose to consider BACs and adenocarcinomas as single group of neoplasms, all of which can display a range of peripheral alveolar wall lepidic growth. The 5-year nonpulmonary metastases-free survival was identical in the patients with neoplasms containing no, less than 5%, and 5% to 25% central fibrosis. Adenocarcinomas with no and less than 5% central fibrosis would be classified morphologically as typical BAC. Those with 5% to 25% central fibrosis would be classified as sclerosing BAC by some and conventional adenocarcinoma with a prominent peripheral BAC growth pattern by others. One possible reason we did not notice a survival difference between patients with adenocarcinomas with no or less than 5% central fibrosis and 5% to 25% central fibrosis was our definition of fibrosis. We considered central fibrosis present when the distinction between malignant cells lining thickened alveolar septa and invasive glands in a desmoplastic stroma became indistinct. Although the precision of this classification may not be apparent within the group of adenocarcinomas that have less than 25% sclerosis, the validity of this definition comes from a continuous decrease in 5-year nonpulmonary metastases with increasing quartile of central fibrosis.
There is evidence of interrelationships between stromal fibrosis, vascular invasion, tumor size, and survival. Stromal invasion often is found in central or subpleural fibrotic foci of adenocarcinomas, where the vascular invasion is most common. 71 Active collagenization frequently occurs in the intermediate regions of adenocarcinomas, at the edge of the solid central scar, 71 where the mean nuclear DNA value is greater than in the peripheral areas without stroma. 27 Higher fibroblastic (central fibrosis) scores are associated with increased vascular space invasion. 91 Lymphatic vascular space invasion has been found to correlate with tumor size within the Tl NO MO neoplasms. 102 The findings of our study support the findings of other authors: patients with Tl NO MO adenocarcinomas constitute a heterogeneous metastasis risk group consisting of patients with a low risk of metastases (<2.0 cm maximum dimension, < 25% central fibrosis, grade 1 or 2 nuclei, and no lymphatic vascular space invasion) and those with a high risk of metastases (>2.0 cm maximum dimension, >50% central fibrosis, grade 3 nuclei, and lymphatic vascular space invasion).
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One use of this study is the identification of patients who may benefit from adjuvant systemic therapy. Although the entire group of patients with Tl NO MO adenocarcinoma and BAC may not benefit from receiving adjuvant therapy, a selected subgroup of patients with a high likelihood of developing metastases may be the optimal group to receive such treatment. 103104 Compared with patients who have clinically proven metastases, the high-risk Tl NO MO group may have a lower metastatic tumor volume, which would possibly provide them with an advantageous response to adjuvant therapy. 105 Additional studies are needed to confirm our findings about the possibility that histologic features of the primary neoplasm that portend a high chance of metastases have micrometastatic lymph node spread at the time of surgery.
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